The effect of the drug/polymer ratio on the properties of the verapamil HCl loaded microspheres

International Journal of Pharmaceutics

Volumn 252, Issue 1-2, 2003, Pages 99-109

  Kiliçarslan, Müge ^a   Baykara, Tamer ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Eudragit RS 100; Microsphere; Solvent evaporation method; Verapamil HCl

Indexed keywords

EUDRAGIT RS; MICROSPHERE; POLYMER; SOLVENT; VERAPAMIL;

ARTICLE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; EVAPORATION; PARTICLE SIZE; PH; PRIORITY JOURNAL; TECHNIQUE; VISCOSITY;

CHEMISTRY, PHARMACEUTICAL; HYDROCHLORIC ACID; MICROSPHERES; POLYMERS; SOLUBILITY; VERAPAMIL;

EID: 0037452432     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00630-0     Document Type: Article

References (35)

1. Ammar H.O., Khalil R.M. Preparation and evaluation of sustained release solid dispersions of drugs with Eudragit polymers. Drug Dev. Ind. Pharm. 23:1997;1043-1054.
2. Benoit, J.P., Marchais, H., Rolland, H., Velde, V.V., 1996. Biodegredable microspheres: advances in production technology. In: Benita, S. (Ed.), Microencapsulation Methods and Industrial Applications. Marcel Dekker, New York, pp. 35-72.
3. Bhardwaj S.B., Shukla A.J., Collins C.C. Effect of varying drug loading on particle size distribution and drug release kinetics of verapamil hydrochloride microspheres prepared with cellulose esters. J. Microencapsul. 12:1995;71-81.
4. Bogataj M., Mrhar A., Kristl A., Kozjek F. Eudragit E microspheres containing bacampicillin: preparation by solvent removal methods. J. Microencapsul. 8:1991;401-406.
5. Chiao C.S.L., Price J.C. Formulation, preparation and dissolution characteristics of propranolol hydrochloride microspheres. J. Microencapsul. 11:1994;153-159.
6. Eichelbaum M., Dengler H.J., Somogyi A., Von Unruh G.E. Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Eur. J. Clin. Pharmacol. 19:1981;127-131.
7. Eudragit Data Sheets, Industrial Products Division, Röhm Pharma GmbH, Weiterstadt, Germany.
8. Follath F., Ha H.R., Schütz E., Bühler F. Pharmacokinetics of conventional and slow-release verapamil. Br. J. Clin. Pharmacol. 21:1986;149S-153S.
9. Follonier N., Doelker E. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. S.T.P. Pharma. Sci. 2:1992;141-158.
10. Gibaldi M., Feldman S. Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to non-disintegrating dosage forms. J. Pharm. Sci. 56:1967;1238-1242.
11. Goracinova K., Klisarova L.J., Simov A. Physical characterization and dissolution properties of verapamil HCl coprecipitates. Drug Dev. Ind. Pharm. 21:1995;383-391.
12. Goto S., Kawata M., Nakamura M., Maekawa K., Aoyama T. Eudragit RS and RL (acrylic resins) microcapsules as pH insensitive and sustained release preparations of ketoprofen. J. Microencapsul. 3:1986a;293-304.
13. Goto S., Kawata M., Nakamura M., Maekawa K., Aoyama T. Eudragit E, L and S (acrylic resins) microcapsules as pH sensitive release preparations of ketoprofen. J. Microencapsul. 3:1986b;305-316.
14. Hamann S.R., Blouin R.A., McAllister R.G. Clinical pharmacokinetics of verapamil. Clin. Pharmacokinet. 9:1984;26-41.
15. Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drug dispersed in solid matrices. J. Pharm. Sci. 52:1963;1145-1149.
16. Kawata M., Nakamura M., Goto S., Aoyama T. Preparation and dissolution pattern of Eudragit RS microcapsules containing ketoprofen. Chem. Pharm. Bull. 34:1986;2618-2623.
17. Kibbe, A.H., 2000. Handbook of Pharmaceutical Excipients, 3rd ed. American Pharmaceutical Association and Pharmaceutical Press, Washington, DC, pp. 401-406.
18. Kim C.K., Kim M.J., Oh K.H. Preparation and evaluation of sustained release microspheres of terbutaline sulfate. Int. J. Pharm. 106:1994;213-219.
19. Kramer, J., Blume, H., 1994. Biopharmaceutical aspects of multiparticulates. In: Ghebre-Sellasie, I. (Ed.), Multiparticulate Oral Drug Delivery. Marcel Dekker, New York, pp. 307-332.
20. Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. J. Pharm. Pharmacol. 24:1972;979-981.
21. Lunden M.T. Nonlinear pharmacokinetics clinical implications. Clin. Pharmacokinet. 20:1991;429-446.
22. Malamataris S., Avgerinos A. Controlled release indomethacin microspheres prepared by using an emulsion solvent-diffusion technique. Int. J. Pharm. 62:1990;105-111.
23. Mattila J., Mäntylä R., Taskinen J., Männistö P. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. Eur. J. Drug Metab. Pharmacokinet. 10:1985;133-138.
24. McTavish D., Sorkin E.M. Verapamil an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 38:1989;19-76.
25. Murthy, K.S., Reiterer, F., Wendt, J., 1994. Packaging of multiparticulate dosage forms materials and equipment. In: Ghebre-Sellassie, I. (Ed.), Multiparticulate Oral Drug Delivery. Marcel Dekker, New York, pp. 405-456.
26. Pongpaibul Y., Price J.C., Whitworth C.W. Preparation and evaluation of controlled release indomethacin microspheres. Drug Dev. Ind. Pharm. 10:1984;1597-1616.
27. Pongpaibul Y., Whitworth C.W. Preparation and in vitro dissolution characteristics of propranolol microcapsules. Int. J. Pharm. 33:1986;243-248.
28. Rawle, A.F., 1993. The importance of particle size analysis in the pharmaceutical industry. Malvern Instruments Application Note Number MRK125-02.
29. Soppimath K.S., Kulkarni A.R., Aminabhavi T.J. Development of hollow microspheres as floating controlled-release systems for cardiovascular drugs: preparation and release characteristics. Drug Dev. Ind. Pharm. 27:2001;507-515.
30. Thies, C., 1992. Formation of degradable drug-loaded microparticles by in-liquid drying processes. In: Donbrow, M. (Ed.), Microcapsules and Nanoparticles in Medicine and Pharmacy. CRC Press, London, pp. 47-71.
31. US Pharmacopeia 24, 2000. US Pharmacopeial Convention, Rockville, MD, pp. 2477-2478 and 1945-1946.
32. Vogelgesang B., Echizen H., Schmidt E., Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br. J. Clin. Pharmacol. 18:1984;733-740.
33. Wingard, L.B., Brody, T.M., Larner, J., Schwartz, A., 1991. Calcium antagonists. In: Kist, K. (Ed.), Human Pharmacology Molecular-to-Clinical. Wolfe Publishing Ltd., London, pp. 212-222.
34. Yüksel N., Baykara T. Preparation of polymeric microspheres by the solvent evaporation method using sucrose stearate as droplet stabilizer. J. Microencapsul. 14:1997;725-733.
35. Yüksel N., Kanik A.E., Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model dependent and independent methods. Int. J. Pharm. 209:2000;57-67.